Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience-Reference-Cited by-同舟云学术

Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience

Published:2019-08 Issue: Volume:85 Page:S1-S9
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Nicolay Uwe,Heijnen Esther,Nacci Pantaleo,Patriarca Peter A.,Leav Brett

Funder

Novartis Vaccines and Diagnostics, Inc.

Seqirus, Inc

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference27 articles.

1. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates;Ansaldi;Vaccine,2010

2. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis;Beyer;Vaccine,2011

3. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes;Calabro;Vaccine,2011

4. Influenza vaccine: the challenge of antigenic drift;Carrat;Vaccine,2007

5. Guidance for Industry. Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines;Center for Biologics Evaluation and Research,2007

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine Versus High-Dose Influenza Vaccine in Older Adults With Influenza Risk Factors During the 2019–2020 US Influenza Season;Open Forum Infectious Diseases;2024-07-30

2. Effectiveness of influenza vaccine among the population in Chongqing, China, 2018–2022: A test negative design-based evaluation;Human Vaccines & Immunotherapeutics;2024-07-18

3. Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies;npj Vaccines;2024-04-10

4. Immunogenicity of Enhanced Influenza Vaccines Against Mismatched Influenza Strains in Older Adults: A Review of Randomized Controlled Trials;Influenza and Other Respiratory Viruses;2024-04

5. A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons;Expert Review of Vaccines;2023-12-19